Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CJM112 in moderate to severe chronic hidradenitis suppurativa
NL-OMON41960Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Aug 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CJM112 in hidradenitis suppurativa (HS) (3 arms), sponsored by Novartis. Primary endpoint: Clinical responder rate at week 16. Started Aug 2015; status: active, not recruiting.
02
Drugs
CJM112
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON41960.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41960.